A population-based case-control study of Selective Serotonin Reuptake Inhibitors (SSRIs) and breast cancer: The impact of duration of use, cumulative dose and latency

BACKGROUND: Selective serotonin reuptake inhibitors (SSRIs), a popular class of antidepressants, may increase breast cancer risk by stimulating the secretion of prolactin, a potential tumour promoter. We evaluated the effects of duration of SSRI use, cumulative dose, and latency on the risk of breas...

Descripción completa

Detalles Bibliográficos
Autores principales: Ashbury, JE, Lévesque, LE, Beck, PA, Aronson, KJ
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2010
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3022871/
https://www.ncbi.nlm.nih.gov/pubmed/21176215
http://dx.doi.org/10.1186/1741-7015-8-90

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3022871/
https://www.ncbi.nlm.nih.gov/pubmed/21176215
http://dx.doi.org/10.1186/1741-7015-8-90

Ejemplares similares